论文部分内容阅读
目的 研究普伐他汀与福辛普利联合使用对糖尿病大鼠肾小球中TGF -β1的影响 ,探讨其对糖尿病肾病的保护机制。方法 将 40只SD大鼠随机分为对照组、糖尿病组、普伐他汀组、普伐他汀联合福辛普利组 (联合组 ) ,每组 10只。给予普伐他汀 (2 0mg·Kg-1·d-1)和福辛普利 (15mg·Kg-1·d-1)治疗 12周后 ,观察大鼠UPE、LDL、Scr及左肾重 /体重 ,免疫组化LSAB法检测肾小球中TGF -β1和FN的表达 ,并采用医学病理图像分析系统测定肾小球系膜基质指数 (M/G)。结果 联合组与普伐他汀组比较 ,各生化指标无显著性差异 ,但UPE、左肾重 /体重比值、M/G明显减少 (P <0 0 5 ) ;肾小球中TGF -β1的表达下调 (P <0 0 5 ) ,同时FN表达亦相应下调(P <0 0 5 )。结论 普伐他汀和福辛普利联合较单独应用普伐他汀使糖尿病大鼠肾小球中TGF -β1的表达下调更明显 ,进一步延缓糖尿病大鼠肾脏病变的进展
Objective To investigate the effect of pravastatin and fosinopril on glomerular TGF-β1 in diabetic rats and its protective mechanism on diabetic nephropathy. Methods 40 SD rats were randomly divided into control group, diabetes group, pravastatin group and pravastatin combined with fosinopril group (combination group), 10 rats in each group. After 12 weeks of treatment with pravastatin (20 mg · kg-1 · d-1) and fosinopril (15 mg · kg-1 · d-1), we observed the changes of UPE, LDL, Scr and left kidney weight / The expressions of TGF-β1 and FN in glomerulus were detected by immunohistochemistry and immunohistochemistry. The glomerular mesangial matrix index (M / G) was determined by the medical pathological image analysis system. Results Compared with the pravastatin group, there was no significant difference in the biochemical indexes between the combined group and the pravastatin group, but the UPE, the ratio of left kidney weight / body weight and M / G were significantly decreased (P <0.05); the expression of TGF-β1 (P <0.05), while the expression of FN was also down-regulated (P <0.05). Conclusions The combination of pravastatin and fosinopril reduces the expression of TGF-β1 in glomeruli of diabetic rats more significantly than pravastatin alone, and further delays the progression of nephropathy in diabetic rats